BRPI0417451A - método de tratar um tumor resistente a interferon - Google Patents

método de tratar um tumor resistente a interferon

Info

Publication number
BRPI0417451A
BRPI0417451A BRPI0417451-8A BRPI0417451A BRPI0417451A BR PI0417451 A BRPI0417451 A BR PI0417451A BR PI0417451 A BRPI0417451 A BR PI0417451A BR PI0417451 A BRPI0417451 A BR PI0417451A
Authority
BR
Brazil
Prior art keywords
interferon
treating
recombinant vectors
resistant tumor
present
Prior art date
Application number
BRPI0417451-8A
Other languages
English (en)
Inventor
William F Benedict
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of BRPI0417451A publication Critical patent/BRPI0417451A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO DE TRATAR UM TUMOR RESISTENTE A INTERFERON". A presente invenção fornece um método para o tratamento de tumores resistentes a interferon, através do uso de vetores recombinantes codificando espécie de interferon. Em particular é observado que a espécie de interferon, provida por vetores recombinantes, possui propriedades não associadas com as proteínas de interferon recombinantemente produzidas. A presente invenção provê ainda composições úteis no tratamento de tumores resistentes a interferon, empregando vetores recombinantes codificando interferons.
BRPI0417451-8A 2003-12-10 2004-12-10 método de tratar um tumor resistente a interferon BRPI0417451A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52852503P 2003-12-10 2003-12-10
PCT/US2004/041307 WO2005058368A1 (en) 2003-12-10 2004-12-10 Methods and compositions for treatment of interferon-resistant tumors

Publications (1)

Publication Number Publication Date
BRPI0417451A true BRPI0417451A (pt) 2007-04-10

Family

ID=34699875

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417451-8A BRPI0417451A (pt) 2003-12-10 2004-12-10 método de tratar um tumor resistente a interferon

Country Status (16)

Country Link
US (7) US7691822B2 (pt)
EP (2) EP2301584A1 (pt)
JP (2) JP4801594B2 (pt)
KR (1) KR101163248B1 (pt)
CN (1) CN1893981B (pt)
AT (1) ATE502654T1 (pt)
AU (1) AU2004298991A1 (pt)
BR (1) BRPI0417451A (pt)
CA (1) CA2548100C (pt)
DE (1) DE602004031973D1 (pt)
ES (1) ES2363912T3 (pt)
IL (1) IL175820A0 (pt)
NO (1) NO20062385L (pt)
SG (2) SG133594A1 (pt)
WO (1) WO2005058368A1 (pt)
ZA (1) ZA200604640B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
PT1456377T (pt) * 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
CN100429220C (zh) * 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
SG133594A1 (en) 2003-12-10 2007-07-30 Canji Inc Methods and compositions for treatment of interferon-resistant tumors
US7851218B2 (en) 2004-12-13 2010-12-14 Schering Corporation Cell lines for production of replication-defective adenovirus
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
WO2007126950A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2276495B1 (en) 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
CA2876656C (en) 2012-06-15 2023-09-26 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
CN113144188A (zh) 2012-09-21 2021-07-23 Pds生物科技公司 改进的疫苗组合物和使用方法
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
KR102129195B1 (ko) * 2016-02-15 2020-07-01 에프케이디 테라피즈 리미티드, 향상된 인터페론 치료
CN109069559A (zh) * 2016-04-14 2018-12-21 崔泽尔有限公司 病毒载体稳定化
WO2019113200A1 (en) * 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
CN111363726A (zh) 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用
US20200222477A1 (en) * 2019-01-10 2020-07-16 Trizell Ltd. Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer
WO2021186246A1 (en) 2020-03-19 2021-09-23 Trizell Ltd. Temperature-responsive virus storage system
KR20230012471A (ko) * 2020-03-30 2023-01-26 트리젤 엘티디. 암 치료용 조성물 및 방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5618711A (en) * 1986-08-22 1997-04-08 Hoffmann-La Roche Inc. Recombinant expression vectors and purification methods for Thermus thermophilus DNA polymerase
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0331635A3 (en) 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
US6207454B1 (en) * 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5120316A (en) * 1990-09-28 1992-06-09 Akzo N.V. Urethral catheter and catheterization process
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
WO1996012406A1 (en) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
WO1997005209A1 (en) 1995-07-28 1997-02-13 Kohne David E Method for enhancing chemiluminescence
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
BR9712362A (pt) * 1996-10-18 1999-08-31 Canji Inc Métodos e composições para distribuição e expressão de ácidos nucléicos de alfa-interferon
US6210969B1 (en) * 1999-04-28 2001-04-03 Coulter International Corp. Composition and method for differentiation of basophil and eosinophil subpopulations of leukocytes in blood
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
PT1456377T (pt) * 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
JP2005531507A (ja) * 2002-03-02 2005-10-20 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法
CA2528136A1 (en) * 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
CN100429220C (zh) * 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
SG133594A1 (en) 2003-12-10 2007-07-30 Canji Inc Methods and compositions for treatment of interferon-resistant tumors
DE602006019916D1 (de) * 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase

Also Published As

Publication number Publication date
US20200164091A1 (en) 2020-05-28
WO2005058368A1 (en) 2005-06-30
JP2007513963A (ja) 2007-05-31
IL175820A0 (en) 2006-10-05
EP1691844B1 (en) 2011-03-23
US20160045618A1 (en) 2016-02-18
US20190374654A1 (en) 2019-12-12
CA2548100A1 (en) 2005-06-30
EP2301584A1 (en) 2011-03-30
KR20060127397A (ko) 2006-12-12
CN1893981A (zh) 2007-01-10
DE602004031973D1 (de) 2011-05-05
NO20062385L (no) 2006-09-05
CN1893981B (zh) 2011-03-23
ATE502654T1 (de) 2011-04-15
CA2548100C (en) 2015-03-24
JP4801594B2 (ja) 2011-10-26
KR101163248B1 (ko) 2012-07-05
SG166117A1 (en) 2010-11-29
AU2004298991A1 (en) 2005-06-30
US9439977B2 (en) 2016-09-13
ZA200604640B (en) 2007-04-25
SG133594A1 (en) 2007-07-30
EP1691844A4 (en) 2007-11-28
US20210322572A1 (en) 2021-10-21
HK1095525A1 (en) 2007-05-11
EP1691844A1 (en) 2006-08-23
US20240000968A1 (en) 2024-01-04
US20050287119A1 (en) 2005-12-29
ES2363912T3 (es) 2011-08-19
US7691822B2 (en) 2010-04-06
JP2011148834A (ja) 2011-08-04
US20100266547A1 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
BRPI0417451A (pt) método de tratar um tumor resistente a interferon
BR0112111A (pt) Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
EP1731605A4 (en) CANCERANT PEPTIDES FROM WT1
CY1118977T1 (el) Επιτοποι σκληροστινης
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
IL175885A0 (en) Monovalent antibody fragments useful as therapeutics
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
CY1111237T1 (el) Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης
BRPI0414497A (pt) análogos de talidomida
BRPI0412265A (pt) uso de calcitonina em osteoartrite
DE60234085D1 (de) Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor
ATE402956T1 (de) Neue, mhc klasse ii assoziierte peptide
ATE495247T1 (de) Chromoprotein und fluoroproteine
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
ATE403729T1 (de) Frostschutzproteine aus basidiomyceten
DE60316821D1 (de) Aminobenzothiazolverbindungen mit nos-hemmender wirkung
ATE482272T1 (de) Zytokinproteinfamilie
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
CY1108280T1 (el) Basb205 πολυπεπτιδια και πολυνουκλεοτιδια που τα κωδικοποιουν
UA88879C2 (en) Fsh glycosylation mutant
ES2138574T3 (es) Composicion inmunogenica a base de particulas liberadas por el tumor.
BRPI0406985A (pt) Terapia de combinação de hcv
ATE441865T1 (de) Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.